Eric Rovers
7 Papers
4 Citations
Eric Rovers is an academic researcher. The author has contributed to research in topics: Antibody & T cell. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.
Cecile Geuijen,Camilla De Nardis,David Maussang,Eric Rovers,Tristan Gallenne,Linda Johanna Aleida Hendriks,Therese Visser,Roy Nijhuis,Ton Logtenberg,John de Kruif,Piet Gros,Mark Throsby +11 more
TL;DR: An unbiased phenotypic combinatorial screening approach is described to identify a bispecific immunoglobulin G1 (IgG1) antibody against HER2 and HER3, which potently inhibits the HRG/HER3 pathway and downstream PI3K/Akt signaling via a "dock & block" mechanism.
103
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Cecile Geuijen,Paul Tacken,Liang Chuan Wang,Rinse Klooster,Pieter Fokko Van Loo,Jing Zhou,Arpita Mondal,Yao bin Liu,Arjen Kramer,Thomas Condamine,Alla Volgina,Linda Johanna Aleida Hendriks,Hans van der Maaden,Eric Rovers,Steef Engels,Floris Fransen,Renate den Blanken-Smit,Vanessa Zondag-van der Zande,Abdul Basmeleh,Willem Bartelink,Ashwini Kulkarni,Wilfred E. Marissen,Cheng Yen Huang,Leslie Hall,Shane Harvey,Soyeon Kim,Marina Martinez,Shaun O'Brien,Edmund K. Moon,Steven M. Albelda,Chrysi Kanellopoulou,Shaun Stewart,Horacio Nastri,Alexander Berthold Hendrik Bakker,Peggy Scherle,Ton Logtenberg,Gregory Hollis,John de Kruif,Reid Huber,Patrick Mayes,Mark Throsby +40 more
TL;DR: In this paper, a human CD137xPD-L1 bispecific antibody, MCLA-145, was identified through functional screening of agonist-and immune checkpoint inhibitor arm combinations.
Abstract LB-261: Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer
Cecile Geuijen,Eric Rovers,Tristan Gallenne,David Andre Baptiste Maussang-Detaille,Arjen Kramer,Nellie Nieuwenhuizen,Carina Clements,Katinka van Zoest,Roy Nijhuis,Therese Visser,Renate den Blanken-Smit,Willem Bartelink,Vanessa Zondag-van der Zande,Linda Kaldenberg,Pieter-Fokko van Loo,Rob Roovers,Robert Doornbos,Leo S. Price,Stefan R. Braam,Setareh van Driel,Lex Bakker,Ton Logtenberg,John de Kruif,Mark Throsby +23 more
TL;DR: The unique simultaneous targeting of MCLA-128 to HER2 and HER3 on HER2-overexpressing breast cancer cells leads to severe impairment of PI3K signaling and reduced cell growth whereas proliferation of primary cardiomyocytes is unaffected.
6
Abstract 539: A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137
Patrick Mayes,Paul Tacken,Steve Wang,Pieter-Fokko van Loo,Thomas Condamine,Hans van der Maaden,Eric Rovers,Steef Engels,Floris Fransen,Ashwini Kulkarni,Yao-bin Liu,Arpita Mondal,Leslie Hall,Soyeon Kim,Marina Martinez,Shaun O'Brien,Edmund K. Moon,Steven M. Albelda,Peggy Scherle,Gregory Hollis,Reid Huber,Mark Throsby,Cecile Geuijen +22 more
TL;DR: The clinical evaluation of MCLA-145 as a novel, PD-L1 dependent CD137 agonist immune therapy is supported and an Fc-silenced bispecific IgG1 antibody to CD137 and PD- L1 with monovalent binding specificity to each target is developed.
3
Abstract 33: The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis
David Andre Baptiste Maussang-Detaille,Camilla De Nardis,Linda Johanna Aleida Hendriks,Carina Bartelink-Clements,Eric Rovers,Tristan Gallenne,Robert Doornbos,Lex Bakker,John de Kruif,Ton Logtenberg,Piet Gros,Cecile Geuijen,Mark Throsby +12 more
TL;DR: The potent anti-proliferative activity of MCLA-128 in vitro and in vivo supports the clinical development of this bispecific HER2xHER3 antibody in HRG-driven tumors.
2